Aimmune Therapeutics, a clinical-stage biopharmaceutical company, is developing desensitization treatments to help protect people with food allergies by potentially reducing the risk of allergic reactions, making accidental exposures to food allergens less dangerous. We are currently conducting Phase 3 studies of our lead product, AR101 for the treatment of peanut allergy.
Aimmune is located in Brisbane, California - the heart of San Francisco's biotechnology hub - with additional offices in the Kings Cross area of London and in Raleigh, North Carolina.